Advanced carcinoma of the pancreas: Phase II study of combined chemotherapy, β-interferon, and retinoids

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 21, Issue 3, 1998, Pages 275-278

  Recchia, Francesco ^a,b,f   Sica, Gigliola ^c   Casucci, Desireè ^b   Rea, Silvio ^b,d   Gulino, Alberto ^b,d   Frati, Luigi ^b,e  

^a ULLS 2 Civilian Hospital   (Italy)

^b CROFI   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d UNIVERSITY OF L'AQUILA   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f NONE   (Italy)

Author keywords

interferon; 5 Fluorouracil; Epirubicin; Mitomycin C; Pancreatic carcinoma; Retinoids

Indexed keywords

BETA INTERFERON; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; MITOMYCIN C; PARACETAMOL; RETINOL PALMITATE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; FEMALE; GASTROINTESTINAL TOXICITY; HEMOLYTIC UREMIC SYNDROME; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METASTASIS; ORAL DRUG ADMINISTRATION; PANCREAS CARCINOMA; PHASE 2 CLINICAL TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; INTERFERON-BETA; LEUCOVORIN; MALE; MIDDLE AGED; MITOMYCIN; PANCREATIC NEOPLASMS; SURVIVAL RATE; VITAMIN A;

EID: 0031814703     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199806000-00014     Document Type: Article

References (34)

1. O'Connell MJ. Current status of chemotherapy for advanced pancreatic and gastric cancer. J Clin Oncol 1985;3:1032-9.
2. Mini E, Trave F, Rustum YM, et al. Enhancement of the antitumor effects of 5-fluorouracil by folinic acid. Pharmacol Ther 1990;47:1-19.
3. Crooke ST, Brander WT. Mitomycin C. A review. Cancer Treat Rev 1976;3:121-4.
4. Wils J, Bleiberg H, Blijiam G, et al. Phase II study of epirubicin in advanced adenocarcinoma of the pancreas. Eur J Cancer Clin Oncol 1985;21:191-4.
5. Bold RJ, Ishizuka J, Townsend CM, et al. All-trans-retinoic acid inhibits growth of human pancreatic cancer cell lines. Pancreas 1996;12:189-95.
6. Rosewicz S, Stier U, Brembeck F, et al. Retinoids: effects on growth, differentiation, and nuclear receptor expression in human pancreatic carcinoma cell lines. Gastroenterology 1995;109:1646-60.
7. Sporn MB, Roberts AB. Interaction of retinoids and transforming growth factor-β in regulation of cell differentiation and proliferation. Mol Endocrinol 1991;5:3-7.
8. Majewski S, Marczack M, Szmurlo A, et al. Retinoids, interferon alpha, 1,25-dihydroxyvitamin D3 and their combination inhibit angiogenesis induced by non-hpv-harboring tumor cell lines. RAR alpha mediates the antiangiogenic effect of retinoids. Cancer Lett 1995;89:117-24.
9. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
10. Borden EC, Hogan TF, Voelkel JG. Comparative antiproliferative activity in vitro of natural interferon alpha and beta for diploid and transformed human cells. Cancer Res 1982; 42:4989-93.
11. Frey JR, Peck R, Bollag W. Antiproliferative activity of retinoids, interferon alpha, and their combination in five human transformed cell lines. Cancer Lett 1991;57:223-7.
12. Toma S, Monteghirfo F, Tasso P, et al. Antiproliferative and synergistic effect of interferon alpha-2a, retinoids and their association in established human cancer cell lines. Cancer Lett 1994;82:209-16.
13. Lama G, Angelucci C, Recchia F, et al. Effect of 13-cis-retinoic acid, tamoxifen and interferon on the growth of human breast cancer cells. Cancer Lett 1996;100:181-9.
14. Spear G, Paulnock D, Jordan RL, et al. Enhancement of monocyte class I and II expression in man by in vivo beta-interferon. Clin Exp Immunol 1987;69:107-15.
15. Prabhala RH, Garenwal HS, Hicks MJ, et al. The effects of 13-cis-retinoic acid and beta-carotene on cellular immunity in humans. Cancer 1991;67:1556-60.
16. Lippman SM, Parkinson DR, Itri LM, et al. 13-cis-retinoic acid plus interferon alpha-2a: highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 1992;84:241-5.
17. Lippman SM, Kavanagh JJ, Peredes-Espinosa M, et al. 13-Cis retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 1992;82:235-41.
18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Journal of the American Statistical Association 1958;53:457-81.
19. Smith F, Hoth D, Levin B, et al. 5-fluorouracil, adriamycin and mitomycin-c (FAM) chemotherapy for advanced adenocarcinoma of the pancreas. Cancer 1980;46:2014-8.
20. The Gastrointestinal Tumor Study Group. Phase II studies of drug combination in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin-c and two regimens of streptozotocin plus mitomycin-c plus fluorouracil. J Clin Oncol 1986;4:1794-8.
21. Weinermann BH, MacCormick RE. A phase II survival comparison of patients with adenocarcinoma of the pancreas treated with 5-fluorouracil and calcium leucovorin versus a matched tumor registry control population. Am J Clin Oncol 1994; 17:467-9.
22. Klijn JG, Hoff AM, Planting AS, et al. Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue sandostatin: a phase II study including endocrine effects. Br J Cancer 1990;64:627-39.
23. Bernhard H, Jager-Arand E, Bernhard G, et al. Treatment of advanced pancreatic cancer with 5-fluorouracil, folinic acid and interferon alpha-2a: results of a phase II trial. Br J Cancer 1995;71:102-5.
24. Moore DF Jr, Pazdur R, Sugarman S, et al. Pilot phase II trial of 13-cis-retinoic acid and interferon-α combination therapy for advanced pancreatic adenocarcinoma. Am J Clin Oncol 1995; 18:525-7.
25. Kimoto Y. Combined effect of interferons alpha, beta and gamma on tumor growth in vitro. Gan To Kagaku Ryoho 1986;13:302-7.
26. Srikland S, Mahdavi V. The induction of differentiation in teratocarcinoma stem cells by retinoic acid. Cell 1980;15:393-403.
27. Lotan R. Effects of vitamin A and its analogues (retinoids) on normal and neoplastic cells. Biochim Biophys Acta 1980; 605:33-91.
28. Marth C, Cronauer MV, Doppler W, et al. Effects of interferons on the expression of the proto-oncogene HER-2 in human ovarian carcinoma cells. Int J Cancer 1992;50:64-8.
29. Sporn M B, Roberts AB. Role of retinoids in differentiation and carcinogenesis. Cancer Res 1983;43:3034-40.
30. Nair S, Mayotte J, Lokshin A, et al. Induction of squamous differentiation by interferon β in a human non-small-cell lung cancer cell line. J Natl Cancer Inst 1994;86:378-83.
31. Sica G, Angelucci C, Marini L, et al. Oncogene expression is modulated by recombinant human interferon-β in human breast cancer cells. Int J Cancer 1996;67:441-6.
32. Lotan R, Xiao-Chun XU, Lippman SM, et al. Suppression of retinoic acid receptor-β in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J Med 1995;332:1405-10.
33. Recchia F, Sica G, De Filippis S, et al. Beta interferon, retinoids and tamoxifen in the treatment of metastatic breast cancer. J Interferon Cytokine Res 1995;15:605-10.
34. Recchia F, Sica G, De Filippis S, Rea S, Frati L. Combined chemotherapy and differentiation therapy in the treatment of advanced non-small-cell lung cancer. Anticancer Res 1997; 17:3761-5.